Resources Repository
-
ArticlePublication 2017Estimating the Fitness Cost and Benefit of Cefixime Resistance in Neisseria Gonorrhoeae
Gonorrhoea is one of the most common bacterial sexually transmitted infections in England, and more …
Gonorrhoea is one of the most common bacterial sexually transmitted infections in England, and more than half of annual infections occur in men who have sex with men (MSM). As the bacterium has developed resistance to each first-line antibiotic in turn, an improved understanding is needed of fitness benefits and costs of antibiotic resistance to inform control policy and planning. The authors developed a stochastic compartmental model representing the natural history and transmission of cefixime-sensitive…
Risk Analysis | Decision Analysis | Science/Technology | Global | Health Systems | Dynamic Transmission | Infectious Diseases | Policy/Regulation | Government/Law | Health/Medicine -
ArticlePublication 2016Economic Evaluation: Bibliometric Analysis of Recent Literature
This bibliometric analysis focuses on recently published full economic evaluations of health interventions and reflects …
This bibliometric analysis focuses on recently published full economic evaluations of health interventions and reflects critically on the implications of the findings. The authors created a database drawing on 14 health, economic, and/or general literature databases for articles published between 1 January 2012 and 3 May 2014 and identified 2844 economic evaluations. They examined the distribution of publications between countries, regions, and health areas studied and compared the relative volume of research with disease burden.…
Benefit-Cost Analysis | Cost-Effectiveness Analysis | Science/Technology | Global | Health Systems | Priority Setting/Ethics | Economics/Finance | Health/Medicine -
ArticlePublication 2016Accounting for Technical, Ethical, and Political Factors in Priority Setting
This article investigates two cases of priority setting to explore how, in addition to technical …
This article investigates two cases of priority setting to explore how, in addition to technical considerations, ethical and political factors shape the allocation of health resources. First, they discuss how Thai authorities adjudicated a coverage decision for HLA-B*1502 screening, which meets the national cost-effectiveness threshold for only some of the conditions it can detect. Second, they consider England’s Cancer Drugs Fund to investigate the interplay of technical decision making and political reality. The findings suggest four concluding…
Cost-Effectiveness Analysis | Science/Technology | Europe | Global | Health Systems | Priority Setting/Ethics | Chronic Disease/Risk | Policy/Regulation | Climate/Environment | Government/Law | Health/Medicine -
ArticlePublication 2017When Cost-Effective Interventions Are Unaffordable
Many health interventions deemed cost-effective are not affordable. Despite the importance of affordability to policymakers, …
Many health interventions deemed cost-effective are not affordable. Despite the importance of affordability to policymakers, little of the cost-effectiveness literature in global health addresses this issue. Budget impact analysis (BIA) describes an intervention's short-term costs and savings from the payer's perspective. This paper assesses the current use of budget impact analysis (BIA) and cost-effectiveness analysis (CEA) in health economic assessments conducted for low- and middle-income countries (LMICs). The authors recommend steps researchers and policymakers can…
Cost-Effectiveness Analysis | Science/Technology | Global | Health Systems | Priority Setting/Ethics | Costing Methods | Infectious Diseases | Chronic Disease/Risk | Economics/Finance | Government/Law | Health/Medicine -
GuidelinesPublication 2016Estimating Health-State Utility for Economic Models: ISPOR Task Force Report
Cost-utility models are increasingly used in many countries to establish whether the cost of a …
Cost-utility models are increasingly used in many countries to establish whether the cost of a new intervention can be justified in terms of health benefits. Health-state utility (HSU) estimates (the preference for a given state of health on a cardinal scale where 0 represents dead and 1 represents full health) are typically among the most important and uncertain data inputs in cost-utility models. Clinical trials represent an important opportunity for the collection of health-utility data.…
Cost-Effectiveness Analysis | Science/Technology | Europe | Health Systems | Preferences/Values | Health Outcomes | Mathematical Models | Technology Assessment | Health/Medicine | North America -
ArticlePublication 2016Essential Package of Cancer Control: Costs, Affordability, and Feasibility of an Essential Package of Cancer Control Interventions in LMIC Countries
Investments in cancer control-prevention, detection, diagnosis, surgery, palliative care-are needed in low-income and particularly in …
Investments in cancer control-prevention, detection, diagnosis, surgery, palliative care-are needed in low-income and particularly in middle-income countries, where most of the world's cancer deaths occur without treatment or palliation. To help countries expand locally appropriate services, Disease Control Priorities, 3rd edition developed an essential package of potentially cost-effective measures for countries to consider and adapt. Interventions included in the package are: prevention of tobacco-related cancer and virus-related liver and cervical cancers; diagnosis and treatment of…
Cost-Effectiveness Analysis | Science/Technology | Global | Health Systems | Costing Methods | Chronic Disease/Risk | Health/Medicine -
ArticlePublication 2016Rotavirus Vaccines Contribute Towards UHC in A Mixed Public–Private Healthcare System
This extended cost-effectiveness analysis (ECEA) evaluates the non-health benefits of rotavirus vaccination in Malaysia from …
This extended cost-effectiveness analysis (ECEA) evaluates the non-health benefits of rotavirus vaccination in Malaysia from the household’s perspective. The authors found that rotavirus vaccination reduces rotavirus episodes and expenditure substantially and provides financial risk protection to all income groups. Although the rich are paying more out of pocket than the poor by utilizing more expensive healthcare, the poor are paying more in proportion to household income. Poverty reduction benefits are concentrated amongst the poorest two…
Cost-Effectiveness Analysis | Science/Technology | Asia & Pacific | Health Systems | Priority Setting/Ethics | Costing Methods | Infectious Diseases | Child/Nutrition | Social Determinants | Economics/Finance | Health/Medicine -
ArticlePublication 2015Achieving a 'Grand Convergence' in Global Health
The Commission on Investing in Health published its report, GlobalHealth2035, in 2013, estimating an investment …
The Commission on Investing in Health published its report, GlobalHealth2035, in 2013, estimating an investment case for a grand convergence in health outcomes globally. In support of the drafting of the Sustainable Development Goals (SDGs), this paper presents estimates of what the grand convergence investment case might achieve—and what investment would be required—by 2030. The authors start with a country-based (bottom-up) analysis of the costs and impact of…!--?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /-->
Cost-Effectiveness Analysis | Science/Technology | Global | Health Systems | Costing Methods | Health Outcomes | Global Governance | Economics/Finance | Health/Medicine -
GuidelinesPublication 2013Economic Analyses to Support Decisions about HPV Vaccination in Low- and Middle-Income Countries: Consensus Report and Guide
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability …
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability before introducing a program for human papillomavirus (HPV) vaccination. However, many such countries lack the technical capacity and data to conduct their own analyses. This report describes the consensus of an expert group convened by the World Health Organization, prioritizing key issues to be addressed when considering economic analyses to support HPV vaccine introduction in these countries. The expert group…
Cost-Effectiveness Analysis | Science/Technology | Asia & Pacific | Health Systems | Costing Methods | Health Outcomes | Infectious Diseases | Chronic Disease/Risk | Economics/Finance | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean